Vivimed Labs

Hyderabad, India Founded: 1988 • Age: 38 yrs Listed
Active pharmaceutical ingredients, formulations, and specialty chemicals are manufactured.
Request Access
Report Incorrect Data
Page last updated

About Vivimed Labs

Vivimed Labs is a publicly listed company based in Hyderabad (India) founded in 1988. Active pharmaceutical ingredients, formulations, and specialty chemicals are manufactured. The company has 59 employees. Vivimed Labs has completed 2 acquisitions, including Klar Sehen Private Limited and UQUIFA Group. Its chief executive, as recorded, is Santosh Varalwar. Its Indian entity Vivimed Labs Limited reported revenue of ₹76.31 Cr. Vivimed Labs offers products and services including Active Pharmaceutical Ingredients and Finished Dosage Formulations. Its focus areas include Biopharma Outsourcing, CDMO and Small Molecules & Peptides. Its competitors include Aurobindo Pharma, Indoco Remedies and Concord Biotech.

Company details

Vivimed Labs is a global supplier of speciality chemicals and pharmaceuticals and a manufacturer of active pharmaceutical ingredients, formulations and active ingredients for Home and Personal Care, hair dyes, imaging chemicals and photochromics. Vivimed Labs has a customer base spread across 50 countries. The company is engaged in the manufacture of Cosmetics, Pharmaceuticals, Nutraceuticals, Photochromics, Natural Actives, Colors and Dyes. Since 2005, Vivimed has expanded rapidly with the acquisition of companies like James Robinson, UK, and Har-Met International Inc. The company currently has 5 manufacturing plants located in India along with RD labs in the UK and India.

  • Headquarters Hyderabad, India
  • Employees 59
  • Stage Public
  • Sectors
    Healthcare
  • Email
    ••••••••
  • Website vivimedlabs.com
  • Social LinkedIn X Facebook
  • Legal Name Vivimed Labs Limited
Operational Areas
Healthcare → Biopharma Outsourcing & Drug Delivery
Key Metrics
  • Market Cap
    ₹51.49 Cr

    VIVIMEDLAB · NSE

  • Share Price
    ₹6.21

    -1.90% today

  • Revenue
    ₹69.99 Cr

    FY 2025-26 · -39.8% YoY

  • EBITDA
    −₹152 Cr

    Margin -217.8%

  • Net Profit
    −₹176 Cr

    FY 2025-26 · -452.2% YoY

  • Latest Funding Round
    $7.5M (USD), Post-IPO

    Jan 2018

  • Investors
    International Finance Corporation

    & 3 more

  • Employee Count
    59
  • Investments & Acquisitions
    Klar Sehen Private Limited

    & 1 more

Products & Services of Vivimed Labs

Vivimed Labs offers a comprehensive portfolio of products and services, including Active Pharmaceutical Ingredients and Finished Dosage Formulations.

Active Pharmaceutical Ingredients
Pharmaceutical Manufacturing

Production of key chemical components for drugs and healthcare products.

Finished Dosage Formulations
Drug Formulation

Development of ready-to-use pharmaceutical products for global markets.

Funding Insights of Vivimed Labs

  • Total Rounds 5
  • Last Round Post-IPO — $7.5M
  • First Round $27.6M

    (Sep 2011)

  • Investors Count 4

All 5 funding rounds of Vivimed Labs with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jan 2018$7.5MPost-IPO––
Orbimed
Sep 2017$42.5MPost-IPO––
Orbimed
Aug 2014$2.6MPost-IPO––
Kitara Capital
Feb 2014$20MPost-IPO––
IFC
Sep 2011$27.6MPost-IPO––
Kitara Capital, Nylim-jb Asset Management
Valuation history

4 investors in total: 4 institutional.

Investors in Vivimed Labs

Vivimed Labs has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include International Finance Corporation, Orbimed and Kitara Capital.

All
Venture Fund
InvestorDescriptionFounded YearDomainLocation
Orbimed
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
1989orbimed.comNew York, United States
Kitara Capital
Investment management and co-investment services through global networks.
kitaracapital.com
International Finance Corporation
IFC is focused on private sector development in emerging markets.
1956ifc.org
Nylim-jb Asset Management
Private equity assets are managed from India by the firm.
nylimjb.netEbene City, Mauritius
Premium access

Investor details for Vivimed Labs

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Vivimed Labs Limited (Vivimed Labs)

Vivimed Labs Limited is the primary company behind Vivimed Labs. The boards of the 6 registered companies of Vivimed Labs currently have 18 directors; the longest-serving is Santosh Varalwar, appointed in 1989. 61 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Santosh Varalwar
DIN 00054763
Managing Director09 Nov 198936 yrs 11 moVivimed Labs Limited, B B R Projects Private Limited, Kreative Hosts Atria Private Limited
Sripad Deshpande Manik Rao
DIN 01898984
Managing Director13 Dec 200718 yrs 10 moKreative Hosts Atria Private Limited
Nirmala Bore
DIN 01890751
Director13 Dec 200718 yrs 10 moKreative Hosts Atria Private Limited
Vithabai Varalwar
DIN 01900637
Director13 Dec 200718 yrs 10 moKreative Hosts Atria Private Limited
Sandeep Varalwar
DIN 01682951
Whole-time director27 Sep 200818 yrsVivimed Labs Limited, B B R Projects Private Limited
Manohar Rao Varalwar
DIN 00059815
Whole-time director14 Aug 201511 yrs 2 moVivimed Labs Limited, B B R Projects Private Limited, Kreative Hosts Atria Private Limited
Venkatavarathan Narasimhan Iyengar
DIN 00418374
Director09 Mar 201610 yrs 7 moKreative Hosts Atria Private Limited
Satyajeet Yashwant Hire
DIN 07108938
Director09 Mar 201610 yrs 7 moKreative Hosts Atria Private Limited
Umesh Pralhadrao Kale
DIN 07486080
Director20 Feb 20197 yrs 8 moStrides Alathur Private Limited
Vikesh Kumar
DIN 07669087
Director20 Feb 20197 yrs 8 moStrides Alathur Private Limited
Tomar Vipin
DIN 08503172
Designated Partner07 Aug 20197 yrs 2 moViv Life Llp
Aparna Bidarkar
DIN 05112945
Director14 Feb 20224 yrs 8 moVivimed Labs Limited, Finoso Pharma Private Limited
Kunapareddy Devi Prasad
DIN 10541141
Additional Director08 Mar 20242 yrs 7 moFinoso Pharma Private Limited
Venkata Seetharama Raju Pakalapati
DIN 07500141
Director25 Apr 20242 yrs 5 moStrides Alathur Private Limited
Varalwar Manas
DIN 08515121
Designated Partner13 Sep 20242 yrs 1 moViv Life Llp
Siva Prasad Jarugula
DIN 07087695
Director11 Dec 20241 yr 10 moVivimed Labs Limited
Subbarathnamma Palepu
DIN 09432984
Director11 Dec 20241 yr 10 moVivimed Labs Limited
Phaninder Nath Peta Sonti
DIN 07074359
Additional Director16 Jul 20251 yr 3 moFinoso Pharma Private Limited

People of Vivimed Labs

7 people are tracked at Vivimed Labs (2 in leadership, 5 in board & advisors); the tracked headcount is 59.

NameRoleGroup
Santosh Varalwar
CEO & MDLeadership
Mark I Robbins
Chief Executive, Uquifa, Vivimed’s API DivisionLeadership
Subhash Varalwar
DirectorBoard & advisors
Jamalapuram Harigopal
DirectorBoard & advisors
Aparna Bidarkar
Independent DirectorBoard & advisors
Manohar Rao
DirectorBoard & advisors
Sandeep Varalwar
DirectorBoard & advisors
Premium access

Complete people profiles for Vivimed Labs

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Vivimed Labs

Vivimed Labs is a publicly listed company on the BSE with ticker symbol VIVIMEDLAB in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date17 Aug 2005
  • Listed onBSE: 532660 · NSE: VIVIMEDLAB
  • Listed entityVivimed Labs Limited
  • Exchange sectorHealth technology
  • ISININE526G01021
  • Share price₹6.78 (-1.45% on the day) · 2026-05-11
  • Market capitalisation₹57.0 Cr
  • EPS (diluted, trailing year)₹-4.21
  • Volume (last session)2,807
  • Analyst consensusNo rating

Financials of Vivimed Labs

Exchange-reported figures of Vivimed Labs Limited, the listed company behind Vivimed Labs (NSE: VIVIMEDLAB).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹69.99 Cr
-39.8% YoY
EBITDA
−₹152 Cr
-1071.6% YoY
Profit After Tax
−₹176 Cr
-452.2% YoY
Net Worth
-
Total Assets
-
Total Debt
-

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue69.991161491872378611,059
Revenue growth-39.8%-22.0%-20.3%-21.2%-72.5%-18.6%-
EBITDA(152)(13.01)(32.88)(187)(7.85)31.5110.24
EBITDA margin-217.8%-11.2%-22.1%-99.9%-3.3%+3.7%+1.0%
Profit before tax(176)(31.84)(45.82)(331)(64.85)(69.87)(109)
Net profit(176)(31.96)(45.44)(329)(67.67)(71.90)(109)
Net profit margin-252.1%-27.5%-30.5%-175.6%-28.5%-8.4%-10.3%
EPS (₹)(20.53)(3.85)(5.48)(39.62)(8.16)(8.67)(13.16)
Balance sheet
Total assets-8178458781,1791,2071,912
Net worth-(35.17)(5.46)39.42364432835
Total debt-376377379359326943
Cash & bank-0.712.033.767.186.4350.49
Net working capital-232246231432455677
Cash flow
Cash from operations-(1.75)(23.99)35.3227.5456779.56
Cash from investing-(4.53)28.29(4.96)(16.41)404(196)
Cash from financing-4.96(6.03)(33.78)(10.38)(1,015)72.44
ParticularsMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024
Revenue12.0015.9920.6121.3925.6136.5124.7729.37
Revenue growth (YoY)-53.1%-56.2%-16.8%-27.2%-33.7%---
Other income5.750.000.210.384.220.070.030.06
EBITDA(140)(10.92)(0.96)(0.28)(2.47)1.06(0.64)(11.00)
EBITDA margin-1169.0%-68.3%-4.7%-1.3%-9.6%+2.9%-2.6%-37.5%
Depreciation11.514.634.905.015.506.624.104.01
Interest0.951.001.660.581.740.480.430.30
Profit before tax(147)(16.55)(7.31)(5.49)(5.49)(5.97)(5.14)(15.25)
Tax0.140.000.000.000.120.000.000.00
Net profit(147)(16.55)(7.31)(5.49)(5.61)(5.97)(5.14)(15.25)
EPS (₹)(17.22)(1.94)(0.85)(0.64)(0.68)(0.70)(0.60)(1.78)
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue55.78104137177218210277
Revenue growth-46.2%-24.3%-22.6%-19.0%+4.0%-24.1%-
EBITDA(150)(14.50)(33.14)(188)(9.04)27.8432.73
EBITDA margin-269.1%-14.0%-24.2%-106.3%-4.1%+13.3%+11.8%
Profit before tax(172)(31.48)(44.39)(330)(64.94)(23.51)(20.74)
Net profit(172)(31.48)(44.39)(328)(67.76)(23.28)(12.30)
Net profit margin-307.7%-30.4%-32.5%-185.5%-31.0%-11.1%-4.5%
EPS (₹)(19.98)(3.80)(5.35)(39.56)(8.17)(2.81)(2.31)
Balance sheet
Total assets-5485936899911,023993
Net worth-58.4989.41133457524554
Total debt-375375377357323304
Cash & bank-0.291.143.356.786.0211.09
Net working capital-166197173372395488
Cash flow
Cash from operations-5.73(96.52)32.8725.3118075.02
Cash from investing-(4.06)99.83(1.60)(11.34)(138)3.32
Cash from financing-(2.53)(5.51)(34.70)(13.21)(46.40)(91.42)
ParticularsMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024
Revenue7.5511.6318.6617.9422.5834.2322.1624.64
Revenue growth (YoY)-66.6%-66.0%-15.8%-27.2%-38.0%---
Other income0.000.000.160.364.150.000.030.00
Total expenses14522.8519.9818.4825.0634.4122.9535.71
EBITDA(137)(11.22)(1.32)(0.54)(2.48)(0.18)(0.79)(11.07)
EBITDA margin-1814.7%-96.5%-7.1%-3.0%-11.0%-0.5%-3.6%-44.9%
Depreciation4.314.404.684.804.616.373.863.79
Interest0.790.941.600.521.480.430.370.25
Profit before tax(142)(16.56)(7.44)(5.50)(4.42)(6.98)(4.99)(15.11)
Tax0.000.000.000.000.000.000.000.00

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 23 Oct 2026
ParticularsMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024
Revenue12.0015.9920.6121.3925.6136.5124.7729.37
Revenue growth (YoY)-53.1%-56.2%-16.8%-27.2%-33.7%---
Other income5.750.000.210.384.220.070.030.06
EBITDA(140)(10.92)(0.96)(0.28)(2.47)1.06(0.64)(11.00)
EBITDA margin-1169.0%-68.3%-4.7%-1.3%-9.6%+2.9%-2.6%-37.5%
Depreciation11.514.634.905.015.506.624.104.01
Interest0.951.001.660.581.740.480.430.30
Profit before tax(147)(16.55)(7.31)(5.49)(5.49)(5.97)(5.14)(15.25)
Tax0.140.000.000.000.120.000.000.00
Net profit(147)(16.55)(7.31)(5.49)(5.61)(5.97)(5.14)(15.25)
EPS (₹)(17.22)(1.94)(0.85)(0.64)(0.68)(0.70)(0.60)(1.78)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue69.991161491872378611,059
Revenue growth-39.8%-22.0%-20.3%-21.2%-72.5%-18.6%-
Other income6.324.379.980.971.279.828.26
Total expenses2221291823742458301,049
Employee cost0.0028.3934.1632.6736.22190233
EBITDA(152)(13.01)(32.88)(187)(7.85)31.5110.24
EBITDA margin-217.8%-11.2%-22.1%-99.9%-3.3%+3.7%+1.0%
Depreciation26.0520.2219.9410818.2855.5066.95
Interest4.172.982.9836.2339.9955.7061.03
Profit before tax(176)(31.84)(45.82)(331)(64.85)(69.87)(109)
Tax0.140.12(0.38)(2.12)2.822.03(0.36)
Net profit(176)(31.96)(45.44)(329)(67.67)(71.90)(109)
Net profit margin-252.1%-27.5%-30.5%-175.6%-28.5%-8.4%-10.3%
EPS (₹)(20.53)(3.85)(5.48)(39.62)(8.16)(8.67)(13.16)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital-16.5816.5816.5816.5816.58342
Reserves & surplus-(51.75)(22.04)22.84348415493
Shareholders' funds (net worth)-(35.17)(5.46)39.42364432835
Minority interest-0.000.000.000.000.000.00
Secured loans-313314317298269833
Unsecured loans-63.3263.3261.9860.6156.27110
Total debt-376377379359326943
Total liabilities-8178458781,1791,2071,912
Assets
Gross block-7527427408027661,274
Net block-4084184365205021,045
Capital work in progress-17.1120.6520.6740.0360.1289.28
Investments-16816819919919985.71
Inventories-58.7664.06161241256502
Sundry debtors-74.1182.8274.1687.36108249
Cash & bank balances-0.712.033.767.186.4350.49
Loans & advances-194194181172159174
Total current assets-328343420507529975
Total current liabilities-95.4896.9718975.5073.25298
Net working capital-232246231432455677
Total assets-8178458781,1791,2071,912
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash-2.033.767.186.4350.4994.50
Net cash from operating activities-(1.75)(23.99)35.3227.5456779.56
Net cash from investing activities-(4.53)28.29(4.96)(16.41)404(196)
Net cash from financing activities-4.96(6.03)(33.78)(10.38)(1,015)72.44
Net change in cash-(1.32)(1.74)(3.42)0.75(44.06)(44.02)
Closing cash-0.712.033.767.186.4350.49
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth-39.8%-22.0%-20.3%-21.2%-72.5%-18.6%-
EBITDA growth-1071.6%+60.4%+82.4%-2282.0%-124.9%+207.7%-
PBT growth-453.8%+30.5%+86.1%-409.9%+7.2%+36.2%-
Net income growth-452.2%+29.7%+86.2%-385.5%+5.9%+34.1%-
Revenue CAGR (3Y)-28.0%-21.2%-44.3%-43.9%-43.5%-10.1%-10.2%
EBITDA CAGR (3Y)-6.6%+18.3%----47.3%-70.6%
Profitability & leverage
Net income margin-252.1%-27.5%-30.5%-175.6%-28.5%-8.4%-10.3%
Return on capital employed-0.0%0.0%0.0%-2.2%-0.9%-2.6%
Return on net worth-0.0%0.0%0.0%-18.8%-16.6%-20.8%
Debt / equity-0.000.002.250.951.071.11
Long-term debt / equity-0.000.000.380.170.440.53
Interest cover-2.34-8.97-5.64-12.26-153.04-232.18-107.62
Efficiency & per share
Fixed asset turnover-0.160.210.260.320.880.90
Inventory turnover-1.891.330.930.962.271.99
Debtors turnover-1.481.902.322.444.833.50
EPS (₹)(20.53)(3.85)(5.48)(39.62)(8.16)(8.67)(13.16)
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)0.00(8.82)(5.24)0.1739.3547.4756.85
ParticularsMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024
Revenue7.5511.6318.6617.9422.5834.2322.1624.64
Revenue growth (YoY)-66.6%-66.0%-15.8%-27.2%-38.0%---
Other income0.000.000.160.364.150.000.030.00
Total expenses14522.8519.9818.4825.0634.4122.9535.71
EBITDA(137)(11.22)(1.32)(0.54)(2.48)(0.18)(0.79)(11.07)
EBITDA margin-1814.7%-96.5%-7.1%-3.0%-11.0%-0.5%-3.6%-44.9%
Depreciation4.314.404.684.804.616.373.863.79
Interest0.790.941.600.521.480.430.370.25
Profit before tax(142)(16.56)(7.44)(5.50)(4.42)(6.98)(4.99)(15.11)
Tax0.000.000.000.000.000.000.000.00
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue55.78104137177218210277
Revenue growth-46.2%-24.3%-22.6%-19.0%+4.0%-24.1%-
Other income0.514.199.570.241.266.086.54
Total expenses206118170365227182244
Employee cost0.0023.0429.4529.6731.6826.4531.87
EBITDA(150)(14.50)(33.14)(188)(9.04)27.8432.73
EBITDA margin-269.1%-14.0%-24.2%-106.3%-4.1%+13.3%+11.8%
Depreciation18.1918.6318.4110717.4515.8016.57
Interest3.862.542.4135.5539.7141.6343.44
Profit before tax(172)(31.48)(44.39)(330)(64.94)(23.51)(20.74)
Tax0.000.000.00(2.12)2.82(0.23)(1.57)
Net profit(172)(31.48)(44.39)(328)(67.76)(23.28)(12.30)
Net profit margin-307.7%-30.4%-32.5%-185.5%-31.0%-11.1%-4.5%
EPS (₹)(19.98)(3.80)(5.35)(39.56)(8.17)(2.81)(2.31)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital-16.5816.5816.5816.5816.5816.58
Reserves & surplus-41.9172.83117441508537
Shareholders' funds (net worth)-58.4989.41133457524554
Secured loans-312312315296267200
Unsecured loans-63.3263.3261.9860.6156.27104
Total debt-375375377357323304
Total liabilities-5485936899911,023993
Assets
Gross block-514507505566536463
Net block-315326343429416356
Capital work in progress-17.1120.6520.6740.0358.4569.77
Investments-58.7858.7816116116187.50
Inventories-56.5062.7778.31239254263
Sundry debtors-45.8059.5450.3063.3976.7089.67
Cash & bank balances-0.291.143.356.786.0211.09
Loans & advances-145152139133122190
Total current assets-248276271442459554
Total current liabilities-81.7079.0297.8369.4963.7365.29
Net working capital-166197173372395488
Total assets-5485936899911,023993
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash-1.143.356.786.0211.0924.16
Net cash from operating activities-5.73(96.52)32.8725.3118075.02
Net cash from investing activities-(4.06)99.83(1.60)(11.34)(138)3.32
Net cash from financing activities-(2.53)(5.51)(34.70)(13.21)(46.40)(91.42)
Net change in cash-(0.86)(2.20)(3.43)0.76(5.07)(13.07)
Closing cash-0.291.143.356.786.0211.09
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth-46.2%-24.3%-22.6%-19.0%+4.0%-24.1%-
EBITDA growth-935.0%+56.3%+82.4%-1978.5%-132.5%-14.9%-
PBT growth-445.2%+29.1%+86.6%-408.4%-176.2%-13.4%-
Net income growth-445.2%+29.1%+86.5%-384.1%-191.1%-89.3%-
Revenue CAGR (3Y)-31.9%-22.0%-13.3%-13.9%-4.6%-7.0%-21.4%
EBITDA CAGR (3Y)-7.2%+17.1%----29.2%-49.3%
Profitability & leverage
Net income margin-307.7%-30.4%-32.5%-185.5%-31.0%-11.1%-6.9%
Return on capital employed-0.0%0.0%0.0%-2.6%+1.9%+3.0%
Return on net worth-0.0%0.0%0.0%-15.0%-4.7%-2.3%
Debt / equity-10.445.131.430.750.630.62
Long-term debt / equity-1.760.850.240.130.120.15
Interest cover-2.29-7.67-4.68-12.06-149.91345.76268.81
Efficiency & per share
Fixed asset turnover-0.220.290.360.430.460.64
Inventory turnover-1.741.941.110.890.811.01
Debtors turnover-1.972.493.113.122.532.89
EPS (₹)(19.98)(3.80)(5.35)(39.56)(8.17)(2.81)(2.31)
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)0.002.476.2011.5050.5758.6762.22

Investments & Acquisitions by Vivimed Labs

Vivimed Labs has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Klar Sehen Private Limited and UQUIFA Group.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
UQUIFA Group
CDMO company manufacturing APIs and intermediates
uquifa.comBarcelona, Spain1936Dec 2011$55M
Klar Sehen Private Limited
Commercial catering and kitchen equipment are supplied nationwide.
klarsehenindia.comKolkata, India1977Oct 2011••••
Premium access

Complete acquisition details for Vivimed Labs

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Vivimed Labs

6 dated milestones of Vivimed Labs across 30 years, from founding to its latest funding, stage changes and deals.

  1. Founded Vivimed Labs is founded.
  2. IPO Lists on the stock exchange (IPO).
  3. Funding First funding round of $27.6M.
  4. Acquisition Acquires Klar Sehen Private Limited.
  5. Acquisition Acquires UQUIFA Group.
  6. Funding Latest funding round, Post-IPO, of $7.5M.

Competitors of Vivimed Labs

Vivimed Labs has 3 listed competitors in our database. They include Aurobindo Pharma, Indoco Remedies and Concord Biotech.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
Aurobindo Pharma
aurobindo.com1986Hyderabad, India1,010
Generic biocatalytic solutions are provided for pharmaceutical applications.
Indoco Remedies
indoco.com1947Mumbai, India6,291
APIs manufacturing and formulation services are provided in therapeutic segments.
Concord Biotech
concordbiotech.com2000Ahmedabad, India1,598
APIs and enzymes are manufactured through fermentation by the CDMO.
Premium access

Detailed competitors of Vivimed Labs

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Vivimed Labs

The website of Vivimed Labs (vivimedlabs.com) receives about 3K visits a month.

  • Monthly visits
    3K

    ▲ 19.9% vs previous month

Similar websites

Websites whose visitors overlap most with Vivimed Labs. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
personalcaremagazine.com
personalcaremagazine.com
100%
#716,064–
en.wikipedia.org
en.wikipedia.org
33%
–
thehindubusinessline.com
thehindubusinessline.com
31%
#21,087–
money.rediff.com
money.rediff.com
23%
#13,922–

Top companies in Biopharma Outsourcing & Drug Delivery

3 companies that operate in the same segment as Vivimed Labs (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Anthem Biosciences
Developer of integrated contract research development and manufacturing services
2007Bengaluru, Karnataka, IndiaUSD 35.74 MUSD 226.38 M1,820
Laurus Labs
Pharmaceutical and biotechnology company
2005Hyderabad, Telangana, IndiaUSD 229.73 MUSD 726.15 M12,470
Entero Healthcare
India's leading healthcare products distribution platform
2018Mumbai, Maharashtra, IndiaUSD 59.67 MUSD 702.49 M4,260
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Vivimed Labs

Bajaj Finance sells Rs 57 crore worth of shares in Strides Pharma
In • 2 years ago
Strides Pharma gains after arm receives USFDA nod for Pregabalin capsule
Moneycontrol • 2 years ago
CMS(00867) Joins Hands with Pharmaron to Promote the Singapore Manufacturing Plant Acquisition and CDMO Business in SEA
China Medical System Holdings Ltd • 2 years ago
Vivimed Labs Says Got Notice From Debt Recovery Tribunal Regarding Application Filed By State Bank Of India
Reuters • 4 years ago
Vivimed Labs Names Ramakanta Tripathy As CFO
Reuters • 4 years ago
Vivimed Labs Consolidated December 2021 Net Sales at Rs 56.52 crore, down 79.66% Y-o-Y
Moneycontrol • 4 years ago
Vivimed Labs Says CEO And CFO Ramesh Krishnamurthy Resigns
Reuters • 5 years ago
Vivimed Labs gets DGHS nod to manufacture, market Favipiravir tablets in India
Indiatimes • 5 years ago
Vivimed Labs Gets Approval To Manufacture & Market Favipiravir Tablet
Reuters • 5 years ago
Vivimed Labs Says Gets Approvals For 3 Products From Manufacturing Site In Hyderabad
Reuters • 5 years ago
Premium access

Complete news archive for Vivimed Labs

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Vivimed Labs

Vivimed Labs was founded in 1988 and raised its 1st funding round 23 years after it was founded.

Vivimed Labs is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.

Santosh Varalwar is the CEO of Vivimed Labs, as recorded in our data.

Vivimed Labs has 59 employees.

The primary company behind Vivimed Labs, Vivimed Labs Limited, reported revenue of ₹76.31 Cr for FY 2026, down 40% year on year.

Vivimed Labs is a global supplier of speciality chemicals and pharmaceuticals and a manufacturer of active pharmaceutical ingredients, formulations and active ingredients for Home and Personal Care, hair dyes, imaging chemicals and photochromics. Vivimed Labs has a customer base spread across 50 countries. The company is engaged in the manufacture of Cosmetics, Pharmaceuticals, Nutraceuticals, Photochromics, Natural Actives, Colors and Dyes. Since 2005, Vivimed has expanded rapidly with the acquisition of companies like James Robinson, UK, and Har-Met International Inc. The company currently has 5 manufacturing plants located in India along with RD labs in the UK and India.

Vivimed Labs's top competitors include Concord Biotech, Indoco Remedies and Aurobindo Pharma.

Vivimed Labs offers Active Pharmaceutical Ingredients and Finished Dosage Formulations.

Yes, Vivimed Labs is publicly traded on BSE under the ticker symbol VIVIMEDLAB.

Vivimed Labs has made 2 acquisitions, including Klar Sehen Private Limited, and UQUIFA Group.

Vivimed Labs has 4 investors. Key investors include International Finance Corporation, Orbimed, Kitara Capital, and Nylim-jb Asset Management.

Vivimed Labs is associated with 6 legal entities: Vivimed Labs Limited, Viv Life Llp, B B R Projects Private Limited and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available